phrykt

10x Genomics, Inc. (TXG): who owns it and who trades it

As of Nov 16, 2026, TXG insiders reported 51 open-market sales worth $18.8M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Serge Saxonov (CEO), with $8.8M. 8 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling 10x Genomics

From the latest filings

Overall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns TXG

393 funds and institutions reported TXG shares worth $5.1B at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $676M.

10 largest owners, by value

FMR LLC (Fidelity)$676M
BlackRock, Inc.$414M
ARK Investment Management LLC$384M
Vanguard Portfolio Management LLC$268M
Quantinno Capital Management LP$210M
Vanguard Capital Management LLC$195M
California State Teachers Retirement System$122M
T. Rowe Price Associates$174M
Sumitomo Mitsui Trust Group, Inc.$161M
Amova Asset Management Americas, Inc.$161M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)17.63M–$676M-1%
BlackRock, Inc.10.80M–$414M+7%
ARK Investment Management LLC10.00M–$384M-15%
Vanguard Portfolio Management LLC6.98M–$268M+1%
Quantinno Capital Management LP5.47M–$210M+1%
Vanguard Capital Management LLC5.08M–$195M-4%
California State Teachers Retirement System4.68M–$122M+3700%
T. Rowe Price Associates4.54M–$174M+2681%
Sumitomo Mitsui Trust Group, Inc.4.19M–$161M-18%
Amova Asset Management Americas, Inc.4.19M–$161M-18%
Morgan Stanley3.35M–$129M+26%
Goldman Sachs Group Inc3.15M–$121M-21%
Geode Capital Management, LLC3.08M–$118M+6%
State Street Corp2.80M–$107M+8%
Citadel Advisors LLC2.78M–$107M+274%
Dimensional Fund Advisors LP2.23M–$85.3M+9%
AQR Capital Management LLC2.03M–$74.7M-20%
Jacobs Levy Equity Management, Inc2.02M–$77.4M-12%
Point72 Asset Management, L.P.1.85M–$71M–
Capital World Investors1.49M–$57.2M+3%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, TXG insiders reported $0 of open-market purchases and $18.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$18.8M
51 trades, 6 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Nov 10, 2026
Filed Nov 13, 2026

Purchases and sales by month

$6.7M$6.7MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Nov 10, 2026Serge SaxonovCEOSale31,000$62.90$1.9MForm 4
Sep 22, 2026Shehnaaz SulimanDirectorSale1,325$80.82$107KForm 4
Sep 22, 2026Shehnaaz SulimanDirectorSale2,270$81.67$185KForm 4
Sep 22, 2026Shehnaaz SulimanDirectorSale292$78.20$22.8KForm 4
Sep 22, 2026Shehnaaz SulimanDirectorSale614$79.51$48.8KForm 4
Sep 22, 2026Shehnaaz SulimanDirectorSale1,222$82.28$101KForm 4
Sep 22, 2026Serge SaxonovCEOSale1,000$78.23$78.2KForm 4
Sep 22, 2026Serge SaxonovCEOSale9,900$81.83$810KForm 4
Sep 22, 2026Serge SaxonovCEOSale9,300$80.90$752KForm 4
Sep 22, 2026Serge SaxonovCEOSale2,000$79.62$159KForm 4
Sep 22, 2026Serge SaxonovCEOSale2,800$82.37$231KForm 4
Sep 9, 2026Adam TaichCFOSale1,206$63.68$76.8KForm 4
Sep 9, 2026Adam TaichCFOSale13,754$65.26$898KForm 4
Sep 9, 2026Adam TaichCFOSale31,428$64.31$2MForm 4
Sep 3, 2026John R StuelpnagelDirectorSale6,814$62.11$423KForm 4
Sep 3, 2026John R StuelpnagelDirectorSale7,012$60.66$425KForm 4
Sep 3, 2026John R StuelpnagelDirectorSale6,174$62.61$387KForm 4
Aug 26, 2026Serge SaxonovCEOSale3,500$63.02$221KForm 4
Aug 26, 2026Serge SaxonovCEOSale6,494$63.98$415KForm 4
Aug 26, 2026Serge SaxonovCEOSale492$64.75$31.9KForm 4
Aug 24, 2026Serge SaxonovCEOSale18,545$63.02$1.2MForm 4
Aug 24, 2026Adam TaichCFOSale17,166$63.02$1.1MForm 4
Aug 24, 2026Benjamin J. HindsonDirectorSale13,818$63.02$871KForm 4
Aug 24, 2026Shehnaaz SulimanDirectorSale561$62.73$35.2KForm 4
Aug 24, 2026Shehnaaz SulimanDirectorSale1,646$63.97$105KForm 4
Aug 14, 2026Sarah A. TeichmannDirectorSale2,273$57.15$130KForm 4
Aug 13, 2026Sarah A. TeichmannDirectorSale5,278$57.29$302KForm 4
Aug 11, 2026John R StuelpnagelDirectorSale3,000$58.73$176KForm 4
Aug 11, 2026John R StuelpnagelDirectorSale17,000$57.58$979KForm 4
Jun 22, 2026Serge SaxonovCEOSale8,527$33.29$284KForm 4
Jun 22, 2026Serge SaxonovCEOSale1,661$36.16$60.1KForm 4
Jun 22, 2026Serge SaxonovCEOSale9,821$35.32$347KForm 4
Jun 22, 2026Serge SaxonovCEOSale9,991$34.28$342KForm 4
Jun 16, 2026Shehnaaz SulimanDirectorSale5,359$32.59$175KForm 4
Jun 16, 2026Shehnaaz SulimanDirectorSale364$33.27$12.1KForm 4
May 26, 2026Serge SaxonovCEOSale10,718$24.71$265KForm 4
May 22, 2026Serge SaxonovCEOSale18,175$24.44$444KForm 4
May 22, 2026Benjamin J. HindsonDirectorSale11,595$24.44$283KForm 4
May 22, 2026Adam TaichCFOSale15,098$24.44$369KForm 4
Apr 14, 2026Serge SaxonovCEOSale5,000$24.56$123KForm 4
Mar 24, 2026Serge SaxonovCEOSale5,000$19.52$97.6KForm 4
Mar 23, 2026Serge SaxonovCEOSale10,000$19.13$191KForm 4
Mar 2, 2026Serge SaxonovCEOSale14,292$22.67$324KForm 4
Mar 2, 2026Serge SaxonovCEOSale1,860$23.18$43.1KForm 4
Feb 25, 2026Sarah A. TeichmannDirectorSale7,579$19.41$147KForm 4
Feb 23, 2026Serge SaxonovCEOSale9,632$18.58$179KForm 4
Feb 23, 2026Adam TaichCFOSale8,968$18.58$167KForm 4
Feb 23, 2026Benjamin J. HindsonDirectorSale7,826$18.58$145KForm 4
Nov 24, 2025Adam TaichCFOSale11,888$19.00$226KForm 4
Nov 24, 2025Benjamin J. HindsonDirectorSale8,283$19.00$157KForm 4
Nov 24, 2025Serge SaxonovCEOSale13,261$19.00$252KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Serge SaxonovChief Executive Officer, Director–$8.8MNov 10, 2026
Adam TaichChief Financial Officer–$4.8MSep 9, 2026
John R StuelpnagelDirector–$2.4MSep 3, 2026
Benjamin J. HindsonSee Remarks, Director–$1.5MAug 24, 2026
Shehnaaz SulimanDirector–$792KSep 22, 2026
Sarah A. TeichmannDirector–$579KAug 14, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TXG short interest

12.47M TXG shares are sold short. Over the last 12 reports the number of shares short went down 44%.

As of Oct 30, 2026, 12.47M TXG shares were sold short, down 2.0% from the report before. At the average daily volume of 3.02M shares, buying them all back would take about 4.1 trading days (days to cover).

Shares short

12.47MMay 15Oct 3023.61M

Days to cover

4.1May 15Oct 308.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.47M–-2%3.02M4.1
Oct 15, 202612.73M–-17%4.80M2.6
Sep 30, 202615.37M–-8%3.39M4.5
Sep 15, 202616.69M–+3%2.35M7.1
Aug 31, 202616.16M–+1%2.93M5.5
Aug 14, 202615.93M–+2%3.48M4.6
Jul 31, 202615.63M–-4%2.70M5.8
Jul 15, 202616.25M–-1%3.04M5.3
Jun 30, 202616.34M–-26%3.88M4.2
Jun 15, 202622.10M–+34%3.26M6.8
May 29, 202616.49M–-26%3.02M5.5
May 15, 202622.15M–+36%2.79M7.9

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

10x Genomics company events

10x Genomics filed 7 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Nov 2, 2026LeadershipUpon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors of 10x Genomics, Inc. appointed Ansuman Satpathy and Joseph Gilliam to the Board of Directors as Class III directors effective immediately, each with a term expiring at the Company's 2028 annual… Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 8, 2026VoteReported shareholder vote results. Filing
  5. May 7, 2026ResultsReleased financial results. Filing
  6. Feb 12, 2026ResultsReleased financial results. Filing
  7. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

10x Genomics financials

Famous investors that hold TXG

8 of the 50 well-known investors we track reported holding TXG in their latest 13F filing. The largest position is Cathie Wood's, worth $567M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 20266.27M$567M3.3%-37%
Andreas Halvorsen · Viking Global InvestorsQ3 2026747,087$67.5M0.2%New
Lee Ainslie · Maverick CapitalQ3 2026538,008$48.6M0.4%New
Israel Englander · Millennium ManagementQ3 2026335,519$30.3M0.0%+187%
Ray Dalio · Bridgewater AssociatesQ3 2026116,482$10.5M0.0%+771%
Steve Cohen · Point72 Asset ManagementQ3 202674,611$6.7M0.0%-96%
Jim Simons · Renaissance TechnologiesQ3 202666,139$6M0.0%-92%
Ken Griffin · Citadel AdvisorsQ3 202615,777$1.4M0.0%-99%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named TXG in the last 120 days.

FiledHolderFormStake
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A14.5%
Nov 16, 2026T. Rowe Price Associates, Inc.13G/A14.5%
Oct 7, 2026ARK Investment Management LLC13G/A5.2%
Oct 7, 2026ARK Investment Management LLC13G/A5.2%

Questions about 10x Genomics, Inc. (TXG) stock

Who owns the most TXG stock?

The largest reported owner of 10x Genomics, Inc. (TXG) is FMR LLC (Fidelity). In total, 393 funds and institutions reported holding TXG at the end of Q2 2026. See the largest owners.

Are TXG insiders buying or selling?

In the last 12 months, TXG insiders reported no open-market purchases and 51 sales worth $18.8M. The latest trade was on Nov 10, 2026. See every trade.

What is the short interest in TXG?

As of Oct 30, 2026, 12.47M TXG shares were sold short, down 2.0% from the report before. At the average daily volume of 3.02M shares, buying them all back would take about 4.1 trading days (days to cover). See the history.

Which famous investors hold TXG?

8 of the 50 well-known investors we track reported TXG in their latest 13F filing, including Cathie Wood, Andreas Halvorsen, Lee Ainslie. The largest position is worth $567M. See all holders.

Executive pay

10x Genomics's chief executive was paid a total of $6.3M for the year ended Dec 31, 2025, down 20% from $7.9M the year before. In the last 12 months, 10x Genomics's executives and directors bought no stock on the open market and sold $18.8M.

Chief executive, total pay$6.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$6.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.